Columnist Betty Vertin is grateful she's been able to manage cold and flu season at home for her three sons with DMD, and her whole family.

The FDA has granted fast track designation to Dyscorban, Cumberland's therapy candidate for heart problems in people with ...

A research collaboration led by the Muscular Dystrophy Association (MDA) aims to create a molecular map of human muscle ...

After realizing that his friends were eager to learn about his MD, columnist Patrick Moeschen became more passionate about ...

An accessibility tool allows columnist Robin Stemple to keep making music. It's an example of how help from friends can jog ...

Columnist Shalom Lim experienced a range of emotions while watching other actors perform a play he wrote about muscular dystrophy.

Three years after Elevidys treatment, boys with DMD show sustained motor function compared with expected disease progression.

Sudden illnesses and recent losses have caused columnist Betty Vertin to reflect on the things worth worrying about, and ...

Leaders with CureDuchenne say approvals are expected this year for several new treatments for Duchenne MD, making it "an ...

An international team of scientists has designed a new type of therapy to target the mutant toxic RNA that causes myotonic dystrophy type 1.

The U.S. Food and Drug Administration has awarded orphan drug status to Atossa Therapeutics' (Z)-endoxifen for Duchenne muscular dystrophy.

Hawken Miller is a talented young journalist who writes feature stories for Muscular Dystrophy News. He covers the latest news and information on a variety of muscular dystrophy topics.